$STRAWBEAR ENT (02125.HK)$According to the preliminary review of the unaudited comprehensive management accounts of the Group for the six months ended June 30, 2024, and the information currently available to the board of directors, the Group is expected to record (i) the shareholders' attributable comprehensive net profit for the six months ended June 30, 2024, is expected to be approximately RMB 29 million to RMB 39 million, compared to approximately RMB 1.3 million for the six months ended June 30, 2023, an increase of approximately 2,075.5% to 2,825.7%; (ii) the adjusted net profit for the six months ended June 30, 2024, is expected to be approximately RMB 36.7 million to RMB 46.7 million, compared to approximately RMB 13.9 million for the six months ended June 30, 2023, an increase of approximately 163.9% to 235.8%.
(ii) The adjusted net profit for the six months ended June 30, 2024 is expected to be approximately RMB 36.7 million to RMB 46.7 million, compared to approximately RMB 13.9 million for the six months ended June 30, 2023, an increase of about 163.9% to 235.8%.
